Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612001092886
Ethics application status
Approved
Date submitted
4/09/2012
Date registered
12/10/2012
Date last updated
12/10/2012
Type of registration
Retrospectively registered
Titles & IDs
Public title
Therapeutic Efficacy Testing of artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum malaria infection in mainland Tanzania
Query!
Scientific title
Therapeutic Efficacy Testing of artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum infection in mainland Tanzania
Query!
Secondary ID [1]
281162
0
Nil
Query!
Universal Trial Number (UTN)
Nil
Query!
Trial acronym
Nil
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malaria
287327
0
Query!
Condition category
Condition code
Infection
287666
287666
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Evaluating the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated P. falciparum infections in Tanzania. Drug will be administered orally using a 6-dose regimen of artemether-lumefantrine (a fixed combination of 20 mg of artemether and 120 mg of lumefantrine in a tablet) twice a day for 3 days. (Patient weighing 5-14kg - one tablet, patients weighing 15-24kg - two tablets, patients weighing 25-35kg - 3 tablets).
Query!
Intervention code [1]
285611
0
Treatment: Drugs
Query!
Comparator / control treatment
N/A -is a one-arm prospective evaluation of clinical and parasitological responses to directly observed treatment for uncomplicated malaria
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
287910
0
Percent of artemether-lumefantrine treatment failure (early treatment failure, late clinical failure, late parasitological failure).
Enrolled patients will be assessed for parasitological (using microscopy), clinical responses during the 28 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.
Query!
Assessment method [1]
287910
0
Query!
Timepoint [1]
287910
0
at day 28 following treatment
Query!
Secondary outcome [1]
299041
0
Percentage of adverse events in all enrolled patients will be documented. Parents or guardians of all enrolled patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form.
Possible medicine related adverse effects include dizziness, itching, vomiting, abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions. However, it is likely that many of these effects are disease-related rather than medicine-induced.
Query!
Assessment method [1]
299041
0
Query!
Timepoint [1]
299041
0
at day 28 following treatment
Query!
Eligibility
Key inclusion criteria
1. Patients aged 6- months-10 years.
2. mono-infection with P. falciparum detected by microscopy;
3. parasitaemia of greater than or equal to 250/microlitre asexual forms;
4. presence of axillary temperature greater than or equal to 37.5 degrees celsius or history of fever during the past 24 hours
5. ability to swallow oral medication;
6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
7. Informed consent from the parent or guardian of children.
Query!
Minimum age
6
Months
Query!
Query!
Maximum age
10
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. presence of general danger signs in children aged 6 months-10 years or signs of severe falciparum malaria according to the definitions of WHO;
2. mixed or mono-infection with another Plasmodium species detected by microscopy;
3. presence of severe malnutrition (defined as a child whose growth standard is below –3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference of less than 110 mm);
4. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
5. regular medication, which may interfere with antimalarial pharmacokinetics;
6. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients with uncomplicated malaria, who meet the study inclusion criteria will be enrolled, treated on site with artemether-lumefantrine and monitored for 28 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
N/A. This is a one arm prospective study in which all eligible patients are given the test drug.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Nil
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/09/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
352
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
4531
0
Tanzania, United Republic Of
Query!
State/province [1]
4531
0
Query!
Funding & Sponsors
Funding source category [1]
285938
0
Other Collaborative groups
Query!
Name [1]
285938
0
USAID
Query!
Address [1]
285938
0
U.S. Agency for International Development
Office of Press Relations
Ronald Reagan Building
Washington, D.C.
20523-0016
Query!
Country [1]
285938
0
United States of America
Query!
Funding source category [2]
285939
0
Other Collaborative groups
Query!
Name [2]
285939
0
World Health Organization
Query!
Address [2]
285939
0
Avenue Appia 20
1211 Geneva 27
Query!
Country [2]
285939
0
Switzerland
Query!
Primary sponsor type
Government body
Query!
Name
Ministry of Health of Tanzania
Query!
Address
P.O. Box 9083
Dar es Salaam
Query!
Country
Tanzania, United Republic Of
Query!
Secondary sponsor category [1]
284762
0
None
Query!
Name [1]
284762
0
Query!
Address [1]
284762
0
Query!
Country [1]
284762
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
287967
0
National Institute for Medical Research
Query!
Ethics committee address [1]
287967
0
P.O. Box 9653
Dar es Salaam
Query!
Ethics committee country [1]
287967
0
Tanzania, United Republic Of
Query!
Date submitted for ethics approval [1]
287967
0
04/03/2012
Query!
Approval date [1]
287967
0
03/05/2012
Query!
Ethics approval number [1]
287967
0
NIMH/HQ/R.8c/Vol. I/205
Query!
Ethics committee name [2]
287968
0
Ethical Review Committee, World Health Organization
Query!
Ethics committee address [2]
287968
0
Avenue Appia 20
1211 Geneva 27
Query!
Ethics committee country [2]
287968
0
Switzerland
Query!
Date submitted for ethics approval [2]
287968
0
24/07/2012
Query!
Approval date [2]
287968
0
28/08/2012
Query!
Ethics approval number [2]
287968
0
RPC533
Query!
Summary
Brief summary
Therapeutic Efficacy Testing of artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum infection in mainland Tanzania
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
34663
0
Query!
Address
34663
0
Query!
Country
34663
0
Query!
Phone
34663
0
Query!
Fax
34663
0
Query!
Email
34663
0
Query!
Contact person for public queries
Name
17910
0
Dr Abdunoor Mulokozi Kabanywanyi
Query!
Address
17910
0
Ifakara Health Institute
Dar es Salaam office
P O Box 78373, Plot 463, Kiko Ave, Mikocheni
Dar es Salaam
Query!
Country
17910
0
Tanzania, United Republic Of
Query!
Phone
17910
0
+255 222 774 714
Query!
Fax
17910
0
Query!
Email
17910
0
[email protected]
Query!
Contact person for scientific queries
Name
8838
0
Dr Abdunoor Mulokozi Kabanywanyi
Query!
Address
8838
0
Ifakara Health Institute
Dar es Salaam office
P O Box 78373, Plot 463, Kiko Ave, Mikocheni
Dar es Salaam
Query!
Country
8838
0
Tanzania, United Republic Of
Query!
Phone
8838
0
+255 222 774 714
Query!
Fax
8838
0
Query!
Email
8838
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF